Halofuginone upregulates the expression of heparanase in thioacetamide-induced liver fibrosis in rats

Laboratory Investigation

Volumn 88, Issue 6, 2008, Pages 627-633

  Ohayon, Olga ^a   Mawasi, Nidal ^a   Pevzner, Anna ^a   Tryvitz, Ana ^a   Gildor, Tsvia ^a   Pines, Mark ^b   Rojkind, Marcos ^c   Paizi, Melia ^a   Spira, Gadi ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b VOLCANI CENTER   (Israel)

^c GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Halofuginone; Heparanase; Hepatic stellate cells; Hydrodynamics based transfection; Rat liver fibrosis; VEGF

Indexed keywords

HALOFUGINONE; HEPARANASE; MESSENGER RNA; THIOACETAMIDE; VASCULOTROPIN; VASCULOTROPIN 165;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; IN VITRO STUDY; LIVER FIBROSIS; LIVER REGENERATION; MALE; NONHUMAN; PARTIAL HEPATECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; STELLATE CELL;

EID: 44349088069     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2008.30     Document Type: Article

References (49)

1. Rojkind M, Giambrone MA, Biempica L. Collagen types in normal and cirrhotic liver. Gastroenterology 1979;76:710-719.
2. Guo J, Friedman SL. Hepatic fibrogenesis. Semin Liver Dis 2007;27:413-426.
3. Iredale JP. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest 2007;117:539-548.
4. Murphy FR, Issa R, Zhou X, et al. Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis. J Biol Chem 2002;277:11069-11076.
5. Iredale JP, Benyon RC, Pickering J, et al. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest 1998;102:538-549.
6. Issa R, Zhou X, Constandinou CM, et al. Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking. Gastroenterology 2004;126:1795-1808.
7. Kjellen L, Lindahl U. Proteoglycans: structures and interactions. Annu Rev Biochem 1991;60:443-475.
8. David G. Integral membrane heparan sulfate proteoglycans. FASEB J 1993;7:1023-1030.
9. Vlodavsky I, Friedmann Y. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest 2001;108:341-347.
10. Parish CR, Freeman C, Hulett MD. Heparanase: a key enzyme involved in cell invasion. Biochim Biophys Acta 2001;1471:M99-M108.
11. Nakajima M, Irimura T, Nicolson GL. Heparanases and tumor metastasis. J Cell Biochem 1988;36:157-167.
12. Vlodavsky I, Friedmann Y, Elkin M, et al. Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat Med 1999;5:793-802.
13. Dempsey LA, Brunn GJ, Platt JL. Heparanase, a potential regulator of cell-matrix interactions. Trends Biochem Sci 2000;25:349-351.
14. Ilan N, Elkin M, Vlodavsky I. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol 2006;38:2018-2039.
15. Goldshmidt O, Yeikilis R, Mawasi N, et al. Heparanase expression during normal liver development and following partial hepatectomy. J Pathol 2004;203:594-602.
16. Granot I, Halevy O, Hurwitz S, et al. Halofuginone: an inhibitor of collagen type I synthesis. Biochim Biophys Acta 1993;1156:107-112.
17. Pines M, Nagler A. Halofuginone: a novel antifibrotic therapy. Gen Pharmacol 1998;30:445-450.
18. Gnainsky Y, Kushnirsky Z, Bilu G, et al. Gene expression during chemically induced liver fibrosis: effect of halofuginone on TGF-beta signaling. Cell Tissue Res 2007;328:153-166.
19. Pines M. Targeting TGF-beta signaling to inhibit fibroblast activation as a therapy for fibrosis and cancer effect of halofuginone. Exp Opinion Drug Discov 2008;3:1-10.
20. Spira G, Mawasi N, Paizi M, et al. Halofuginone, a collagen type I inhibitor improves liver regeneration in cirrhotic rats. J Hepatol 2002;37:331-339.
21. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-699.
22. Lopez-De Leon A, Rojkind M. A simple micromethod for collagen and total protein determination in formalin-fixed paraffin-embedded sections. J Histochem Cytochem 1985;33:737-743.
23. Jamall IS, Finelli VN, Que Hee SS. A simple method to determine nanogram levels of 4-hydroxyproline in biological tissues. Anal Biochem 1981;112:70-75.
24. Jonsson JR, Clouston AD, Ando Y, et al. Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. Gastroenterology 2001;121:148-155.
25. Greenwel P, Schwartz M, Rosas M, et al. Characterization of fat-storing cell lines derived from normal and CCl4-cirrhotic livers. Differences in the production of interleukin-6. Lab Invest 1991;65:644-653.
26. Greenwel P, Rubin J, Schwartz M, et al. Liver fat-storing cell clones obtained from a CCl4-cirrhotic rat are heterogeneous with regard to proliferation, expression of extracellular matrix components, interleukin-6, and connexin 43. Lab Invest 1993;69:210-216.
27. Gnainsky Y, Spira G, Paizi M, et al. Halofuginone, an inhibitor of collagen synthesis by rat stellate cells, stimulates insulin-like growth factor binding protein-1 synthesis by hepatocytes. J Hepatol 2004;40:269-277.
28. Popov Y, Patsenker E, Bauer M, et al. Halofuginone induces matrix metalloproteinases in rat hepatic stellate cells via activation of p38 and NFkappaB. J Biol Chem 2006;281:15090-15098.
29. Yeikilis R, Gal S, Kopeiko N, et al. Hydrodynamics based transfection in normal and fibrotic rats. World J Gastroenterol 2006;12:6149-6155.
30. Zetser A, Bashenko Y, Edovitsky E, et al. Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation. Cancer Res 2006;66:1455-1463.
31. Michalopoulos GK, DeFrances MC. Liver regeneration. Science 1997;276:60-66.
32. Fausto N. Liver regeneration. J Hepatol 2000;32:19-31.
33. Li D, Friedman SL. Liver fibrogenesis and the role of hepatic stellate cells: new insights and prospects for therapy. J Gastroenterol Hepatol 1999;14:618-633.
34. Benyon RC, Iredale JP. Is liver fibrosis reversible? Gut 2000;46:443-446.
35. Elkin M, Ilan N, Ishai-Michaeli R, et al. Heparanase as mediator of angiogenesis: mode of action. FASEB J 2001;15:1661-1663.
36. Ben-Zaken O, Gingis-Velitski S, Vlodavsky I, et al. Heparanase induces Akt phosphorylation via a lipid raft receptor. Biochem Biophys Res Commun 2007;361:829-834.
37. Gingis-Velitski S, Zetser A, Flugelman MY, et al. Heparanase induces endothelial cell migration via protein kinase B/Akt activation. J Biol Chem 2004;279:23536-23541.
38. Nobuhisa T, Naomoto Y, Okawa T, et al. Translocation of heparanase into nucleus results in cell differentiation. Cancer Sci 2007;98:535-540.
39. Nagler A, Firman N, Feferman R, et al. Reduction in pulmonary fibrosis in vivo by halofuginone. Am J Respir Crit Care Med 1996;154:1082-1086.
40. Su AI, Guidotti LG, Pezacki JP, et al. Gene expression during the priming phase of liver regeneration after partial hepatectomy in mice. Proc Natl Acad Sci USA 2002;99:11181-11186.
41. Assy N, Spira G, Paizi M, et al. Effect of vascular endothelial growth factor on hepatic regenerative activity following partial hepatectomy in rats. J Hepatol 1999;30:911-915.
42. Kraizer Y, Mawasi N, Seagal J, et al. Vascular endothelial growth factor and angiopoietin in liver regeneration. Biochem Biophys Res Commun 2001;287:209-215.
43. Zhou X, Jamil A, Nash A, et al. Impaired proteolysis of collagen I inhibits proliferation of hepatic stellate cells: implications for regulation of liver fibrosis. J Biol Chem 2006;281:39757-39765.
44. McGaha TL, Phelps RG, Spiera H, et al. Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth- factor-beta-mediated Smad3 activation in fibroblasts. J Invest Dermatol 2002;118:461-470.
45. Ramadori G, Saile B. Portal tract fibrogenesis in the liver. Lab Invest 2004;84:153-159.
46. Krull NB, Zimmermann T, Gressner AM. Spatial and temporal patterns of gene expression for the proteoglycans biglycan and decorin and for transforming growth factor-beta 1 revealed by in situ hybridization during experimentally induced liver fibrosis in the rat. Hepatology 1993;18:581-589.
47. Novosyadlyy R, Dargel R, Scharf JG. Expression of insulin-like growth factor-I and insulin-like growth factor binding proteins during thioacetamide-induced liver cirrhosis in rats. Growth Horm IGF Res 2005;15:313-323.
48. Guyot C, Combe C, Clouzeau-Girard H, Moronvalle-Halley V, Desmoulière A. Specific activation of the different fibrogenic cells in rat cultured liver slices mimicking in vivo situations. Virchows Arch 2007;450:503-512.
49. Bruck R, Genina O, Aeed H, et al. Halofuginone to prevent and treat thioacetamide-induced liver fibrosis in rats. Hepatology 2001;33:379-386.